TECH Stock Analysis: Buy, Sell, or Hold?
TECH - Bio-Techne Corp.
$44.81
-0.08 (-0.18%)
▼
5d:
-11.98%
30d:
-23.39%
90d:
-24.74%
HOLD
MODERATE Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 06, 2026
0d
Get Alerted When TECH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called TECH this week
0% bullish • 2 bearish
0% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TECH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: TECH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$68.15
Based on 5.7% avg growth
INTRINSIC VALUE TODAY
$42.31
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TECH is currently trading at $44.81, which is considered oversold relative to its 30-day fair value range of $49.62 to $58.28. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.7) compared to its historical average (27.3). Remarkably, the market is currently pricing in an annual earnings decline of 7.3% over the next few years. This pessimistic expectation contrasts with the company's recent 128.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TECH is in a strong downtrend. The price is currently testing key support at $44.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TECH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $62.64 (+39.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TECH is in a strong downtrend. The price is currently testing key support at $44.12. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TECH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $62.64 (+39.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$49.62 -
$58.28
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.5% below Wall St target ($62.64)
- CAUTION: 5-day price weakness (-12.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$49.62 -
$58.28
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$44.12
Resistance Level
$57.01
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.72
Wall Street Target
$62.64
(+39.5%)
Revenue Growth (YoY)
-1.5%
Earnings Growth (YoY)
128.6%
Profit Margin
9.0%
Valuation Discount vs History
-7.3% cheaper
PE vs Historical
21.7 vs 27.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.3%
(market-implied from PE analysis)
1-Year Target
$41.61
(-7%)
2-Year Target
$38.58
(-14%)
3-Year Target
$35.76
(-20%)
3-Yr Target (if PE normalizes)
(PE: 22→27)
$44.94
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 7.4%)
$56.50
(+26%)
Base:
(SPY PE: 21.7, Growth: 7.4%)
$55.68
(+24%)
Bear:
(PE: 18.5, Growth: 7.4%)
$47.33
(+5%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (22x PE) as earnings recover.
Forward PE: 23.15 | Forward EPS (Implied): $1.94
Bull Case
$54.20
(+21%)
Analyst growth 15.0%, PE expands to 24.3
Base Case
$44.89
(0%)
Market implied 0.0%, PE stable at 23.2
Bear Case
$34.34
(-24%)
Severe decline -15.0%, PE contracts to 20.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.7 to 27.3
Stabilization Target:
$56.42
(+25.7%)
PE Expansion Potential:
+25.7%
Share & Embed Analysis
Last updated: May 14, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECH showing a specific setup today?
Insider Activity (6 Months)
4
Buys
3
Sells
+
Net
NEUTRAL
Recent Transactions
Ro Khanna
BUY
2026-03-30
April McClain Delaney
SELL
2026-03-26
April McClain Delaney
SELL
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 60 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 59 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
